Analysts Offer Insights on Healthcare Companies: Epizyme (EPZM), Verastem (VSTM) and MannKind (MNKD)


There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Epizyme (NASDAQ:EPZM), Verastem (NASDAQ:VSTM) and MannKind (NASDAQ:MNKD) with bullish sentiments.

Epizyme (EPZM)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Epizyme, with a price target of $25. The company’s shares closed yesterday at $10.25, close to its 52-week low of $8.61.

Fein observed:

“Our price target of $25 for EPZM is based on a probability-adjusted sum-of-parts NPV-DCF: $3.1 (Taz, DLBCL, EZH2mut) + $16.2 (Taz, FL, EZH2mut) + $1.3 (Taz, INI- solid tumor) + $0.9 (DOT1L inhibitor) + $3.1 (cash). Risks to our investment thesis and target price include: (1) failure in clinical trials; (2) failure to secure regulatory approvals; and (3) a smaller-than-anticipated commercial opportunity due to market sizing, competition, and pricing. Epizyme, Inc.”

According to TipRanks.com, Fein is a 4-star analyst with an average return of 9.3% and a 46.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as Proteostasis Therapeutics Inc, ACADIA Pharmaceuticals Inc, and Strongbridge Biopharma Plc.

Currently, the analyst consensus on Epizyme is a Strong Buy with an average price target of $23.67, representing a 130.9% upside. In a report issued on September 21, Citigroup also maintained a Buy rating on the stock.

.

See today’s analyst top recommended stocks >>

Verastem (VSTM)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Verastem, with a price target of $15. The company’s shares closed yesterday at $8.94.

Ramakanth said:

“We maintain our Buy rating of VSTM and raise our 12-month price target to $15.00 per share, up from $10.00. We derive our price target based on the average of two valuation methods: 1) price-sales multiple analysis applying an 8x multiple to our 2025 sales estimate discounted at 12%; and 2) price-earnings multiple analysis applying an 18x multiple to our 2025 estimated earnings discounted at 12%. (1) clinical; (2) regulatory; (3) financial; (4) commercial; and (5) intellectual property.”

According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.7% and a 41.5% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Leap Therapeutics Inc.

Verastem has an analyst consensus of Strong Buy, with a price target consensus of $14.20, representing a 58.9% upside. In a report released today, Oppenheimer also assigned a Buy rating to the stock with a $16 price target.

.

MannKind (MNKD)

In a report released today, Oren Livnat from H.C. Wainwright maintained a Buy rating on MannKind, with a price target of $4. The company’s shares closed yesterday at $1.92, close to its 52-week low of $0.98.

According to TipRanks.com, Livnat is a 3-star analyst with an average return of 2.9% and a 53.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Zynerba Pharmaceuticals, Pacira Pharmaceuticals, and Jazz Pharmaceuticals.

MannKind has an analyst consensus of Moderate Buy, with a price target consensus of $4.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MNKD:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts